Illumina, Inc. (ILMN) stock analysis
Healthcare · Diagnostics & Research
From the 10-K filed 2026-02-12
Business type: Treadmill
How it makes money
Customers pay for sequencing systems and consumables to perform genetic analysis.
Research centers, hospitals, and biotechnology companies pay for sequencing systems and the consumables used to run them.
Profitability is driven by the tension between falling sequencing costs and the resulting demand for new applications.
What protects it: the moat
Management claims it is a global leader in DNA sequencing and array-based technologies.
The company asserts that its focus on innovation has allowed it to establish a leading position in the market for genomic analysis.
What growth costs
Illumina reinvests in research and uses cash for acquisitions to grow its business.
It invests in research and development and pursues acquisitions.
For instance, it paid $350 million in cash to acquire assets from Standard BioTools to enter the proteomics market.
What could damage it
Falling sequencing costs could impair earnings if demand for products does not increase proportionately.
As sequencing technology becomes cheaper, the company relies on a massive increase in usage to offset lower prices. If the volume of new applications does not rise at a rate that matches the falling costs, results of operations will be adversely affected.
About Illumina, Inc.
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. The company has a collaboration with Labcorp Holdings Inc. for the development of oncology treatments through applications of sequencing solutions across the healthcare ecosystem; and strategic collaboration with Integrated DNA Technologies to enable a DRAGEN, secondary analysis pipeline for IDT xGena, FFPE and cfDNA next generation sequencing (NGS) library preparation with custom panels, delivering an integrated, end-to-end solution for somatic oncology research. It also has a data partnership with Center for Data-Driven Discovery in Biomedicine to advance research in pediatric cancer and rare disease. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.